Extracellular-Vesicle-Based Cancer Panels Diagnose Glioblastomas with High Sensitivity and Specificity.

Area of Science:

• Neuro-oncology
• Molecular diagnostics
• Biomarker discovery

Background:

• Glioblastoma is a highly aggressive central nervous system neoplasm.
• Current diagnostic and monitoring methods for glioblastoma have limitations.
• Serum extracellular vesicles (EVs) present a promising source for non-invasive biomarkers.

Purpose of the Study:

• To develop and validate serum EV-based biomarker panels for glioblastoma diagnosis.
• To assess the utility of these panels in monitoring tumor burden, progression, and treatment response.
• To establish a minimally invasive diagnostic tool for glioblastoma management.

Main Methods:

• RNA sequencing was performed on RNA isolated from serum EVs of glioblastoma patients (n=85) and healthy controls (n=31).
• Differentially expressed genes (DEGs) between groups were identified (2XFC, FDR < 0.05).
• Serum-EV-based biomarker panels were constructed using identified DEGs.

Main Results:

• 569 differentially expressed genes (DEGs) were identified in preoperative glioblastoma EVs compared to controls.
• Developed biomarker panels demonstrated high diagnostic performance: wild-type IDH1 (96% sensitivity/80% specificity), MGMT promoter methylation (91% sensitivity/73% specificity), p53 mutation (100% sensitivity/89% specificity), and TERT promoter mutation (89% sensitivity/100% specificity).
• This study is the first to demonstrate the efficacy of serum-EV-based panels for glioblastoma diagnosis.

Conclusions:

• Serum extracellular vesicle (EV)-based biomarker panels can accurately diagnose glioblastomas.
• These panels show high sensitivity and specificity for detecting key molecular alterations in glioblastoma.
• Serum EV analysis offers a promising avenue for non-invasive glioblastoma diagnostics and treatment monitoring.